Hernández Mariely, Levin Frances R, Campbell Aimee N C
Department of Psychiatry, Columbia University Irving Medical Center, New York, USA.
Division on Substance Use Disorders, New York State Psychiatric Institute, 1051 Riverside Dr., Unit 20, New York, NY, 10032, USA.
CNS Drugs. 2025 May;39(5):457-472. doi: 10.1007/s40263-025-01168-6. Epub 2025 Feb 20.
Attention deficit hyperactivity disorder (ADHD) is notably overrepresented in substance use treatment centers, with an estimated prevalence of 21-23% when screening practices are implemented. Many adults in these settings receive an ADHD diagnosis for the first time, highlighting the frequent underdiagnosis of ADHD among individuals seeking treatment for alcohol and substance use issues. Additionally, those entering treatment programs represent only a small fraction of the broader population with problematic alcohol use. This review explores the research on the prevalence and treatment of co-occurring ADHD and substance use disorders (SUD), with a particular emphasis on alcohol use disorders (AUD) as the most common SUD. It also provides clinical guidelines for the screening and diagnosis of ADHD in patients with active alcohol and substance use and offers recommendations to enhance screening practices and improve access to treatment for individuals with co-occurring ADHD and AUD.
注意缺陷多动障碍（ADHD）在物质使用治疗中心的比例显著过高，当实施筛查措施时，估计患病率为21%-23%。在这些机构中，许多成年人首次被诊断出患有ADHD，这凸显了在寻求酒精和物质使用问题治疗的个体中，ADHD经常未被诊断出来。此外，进入治疗项目的人仅占酒精使用有问题的更广泛人群的一小部分。本综述探讨了共病ADHD和物质使用障碍（SUD）的患病率及治疗的研究，特别强调酒精使用障碍（AUD）作为最常见的SUD。它还为正在积极使用酒精和物质的患者的ADHD筛查和诊断提供临床指南，并提出建议以加强筛查措施，改善共病ADHD和AUD个体的治疗可及性。
